Chieh-Chen Wu1,2, An-Jen Lee1,3, Chun-Hsien Su4, Chu-Ya Huang1,5, Md Mohaimenul Islam6, Yung-Ching Weng1. 1. Department of Healthcare Information and Management, School of Health Technology, Ming Chuan University, Taipei 333, Taiwan. 2. Department of Exercise and Health Promotion, College of Kinesiology and Health, Chinese Culture University, 55 Yangmingshan, Huagang Road, Shilin District, Taipei 11114, Taiwan. 3. Southeast Asian, Cross-Strait and Overseas Student Institute, Ming Chuan University, Taipei 333, Taiwan. 4. Graduate Institute of Sport Coaching Science, College of Kinesiology and Health, Chinese Culture University, Taipei 11114, Taiwan. 5. Taiwan College of Healthcare Executives, 9F No. 95, Sec. 3, Roosevelt Rd., Da'an District, Taipei City 106607, Taiwan. 6. Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Abstract
BACKGROUND: Recent epidemiological studies remain controversial regarding the association between statin use and reducing the risk of mortality among individuals with COVID-19. OBJECTIVE: The objective of this study was to clarify the association between statin use and the risk of mortality among patients with COVID-19. METHODS: We conducted a systematic articles search of online databases (PubMed, EMBASE, Scopus, and Web of Science) between 1 February 2020 and 20 February 2021, with no restriction on language. The following search terms were used: "Statins" and "COVID-19 mortality or COVID19 mortality or SARS-CoV-2 related mortality". Two authors individually examined all articles and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for study inclusion and exclusion. The overall risk ratio (RRs) with 95% confidence interval (CI) was calculated to show the strength of the association and the heterogeneity among the studies was presented Q and I2 statistic. RESULTS: Twenty-eight studies were assessed for eligibility and 22 studies met the inclusion criteria. Statin use was associated with a significantly decreased risk of mortality among patients with COVID-19 (RR adjusted = 0.64; 95% CI: 0.57-0.72, p < 0.001). Moreover, statin use both before and after the admission was associated with lowering the risk of mortality among the COVID-19 patients (RR adjusted;before = 0.69; 95% CI: 0.56-0.84, p < 0.001 and RR adjusted;after = 0.57; 95% CI: 0.54-0.60, p < 0.001). CONCLUSION: This comprehensive study showed that statin use is associated with a decreased risk of mortality among individuals with COVID-19. A randomized control trial is needed to confirm and refute the association between them.
BACKGROUND: Recent epidemiological studies remain controversial regarding the association between statin use and reducing the risk of mortality among individuals with COVID-19. OBJECTIVE: The objective of this study was to clarify the association between statin use and the risk of mortality among patients with COVID-19. METHODS: We conducted a systematic articles search of online databases (PubMed, EMBASE, Scopus, and Web of Science) between 1 February 2020 and 20 February 2021, with no restriction on language. The following search terms were used: "Statins" and "COVID-19mortality or COVID19mortality or SARS-CoV-2 related mortality". Two authors individually examined all articles and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for study inclusion and exclusion. The overall risk ratio (RRs) with 95% confidence interval (CI) was calculated to show the strength of the association and the heterogeneity among the studies was presented Q and I2 statistic. RESULTS: Twenty-eight studies were assessed for eligibility and 22 studies met the inclusion criteria. Statin use was associated with a significantly decreased risk of mortality among patients with COVID-19 (RR adjusted = 0.64; 95% CI: 0.57-0.72, p < 0.001). Moreover, statin use both before and after the admission was associated with lowering the risk of mortality among the COVID-19patients (RR adjusted;before = 0.69; 95% CI: 0.56-0.84, p < 0.001 and RR adjusted;after = 0.57; 95% CI: 0.54-0.60, p < 0.001). CONCLUSION: This comprehensive study showed that statin use is associated with a decreased risk of mortality among individuals with COVID-19. A randomized control trial is needed to confirm and refute the association between them.
Authors: Adrian H Heald; David A Jenkins; Richard Williams; Matthew Sperrin; Rajshekhar N Mudaliar; Akheel Syed; Asma Naseem; Kelly A Bowden Davies; Yonghong Peng; Niels Peek; William Ollier; Simon G Anderson; Gayathri Delanerolle; J Martin Gibson Journal: Diabetes Ther Date: 2022-04-13 Impact factor: 3.595